HBV Enhances Sorafenib Resistance in Hepatocellular Carcinoma by Reducing Ferroptosis via SRSF2-Mediated Abnormal PCLAF Splicing

Hepatocellular carcinoma (HCC) is one of the most lethal human cancers. Hepatitis B virus (HBV) infection accounts for nearly 50% of HCC cases. Recent studies indicate that HBV infection induces resistance to sorafenib, the first-line systemic treatment for advanced HCC for more than a decade, from...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Lijuan, Lv, Zhao, Wang, Miao, Zhang, Dongyan, Liu, Dongying, Zhu, Fan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9967099/
https://www.ncbi.nlm.nih.gov/pubmed/36834680
http://dx.doi.org/10.3390/ijms24043263

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9967099/
https://www.ncbi.nlm.nih.gov/pubmed/36834680
http://dx.doi.org/10.3390/ijms24043263

Ejemplares similares